Search
Cyproterone acetate
go.drugbank.com/drugs/DB04839ApprovedInvestigationalIt is used in the treatment of hypersexuality in males, as a palliative in prostatic carcinoma, and, in combination with estrogen, for the therapy of severe acne and hirsutism in females.
Mixtures: DONABELLA® 2 MG /0.035 MG, DONABELLA® 2 MG /0.035 MGCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InhibitorsMepenzolate
go.drugbank.com/drugs/DB04843ApprovedWithdrawnPharmacologically, it is a post-ganglionic parasympathetic inhibitor. … Mepenzolate is a post-ganglionic parasympathetic inhibitor. It decreases gastric acid and pepsin secretion and suppresses spontaneous contractions of the colon.
Categories: Heterocyclic Compounds, 1-RingTetrabenazine
go.drugbank.com/drugs/DB04844ApprovedA drug formerly used as an antipsychotic but now used primarily in the symptomatic treatment of various hyperkinetic disorders. … It is a monoamine depletor and used as symptomatic treatment of chorea associated with Huntington's disease. FDA approved on August 15, 2008.
Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 2-RingSynonyms: 1,2,4,6,7,11b-hexahydro-3-isobutyl-9,10-dimethoxy-2H-benzo[a]quinolizin-2-one, 2-oxo-3-isobutyl-9,10-dimethoxy-1,2,3,4,6,7-hexahydro-11bH-benzo[a]quinolizineIxabepilone
go.drugbank.com/drugs/DB04845ApprovedInvestigationalIxabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. … Ixabepilone is a semisynthetic analogue of epothilone B. It has a lactone–lactam modification that minimizes susceptibility to esterase degradation.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexSynonyms: Azaepothilone B, Aza-epothilone BCeliprolol
go.drugbank.com/drugs/DB04846ApprovedInvestigationalWithdrawnIt is simultaneously a selective β1 receptor antagonist, a β2 receptor partial agonist and a weak α2 receptor antagonist. … In 2010 a clinical trial has suggested a use for this medication in the prevention of vascular complications of a rare inherited disease called vascular Ehlers–Danlos syndrome.
Categories: Cytochrome P-450 Substrates, Adrenergic beta-2 Receptor AgonistsSynonyms: RS)-N'-{3-acetyl-4-[3-(tert-butylamino)-2-hydroxypropoxy]phenyl}-N,N-diethylureaAZD0947
go.drugbank.com/drugs/DB04848ExperimentalAZD0947 is a K+ channel opener, which was under investigation by AstraZeneca for the treatment of overactive bladder.
Biricodar
go.drugbank.com/drugs/DB04851InvestigationalThe pipecolinate derivative biricodar (VX-710) is a clinically applicable modulator of P-glycoprotein (Pgp) and multidrug resistance protein (MRP-1).
Categories: P-glycoprotein inhibitors, Heterocyclic Compounds, 1-RingImplitapide
go.drugbank.com/drugs/DB04852InvestigationalImplitapide is a microsomal triglyceride transfer protein (MTP)-inhibitor.
Categories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds, 2-RingBinodenoson
go.drugbank.com/drugs/DB04853InvestigationalThis specificity allows Binodenoson to deliver - in a single injection - a more effective dose of medication with fewer side effects than current treatments, which typically require a 15-20 minute infusion … Binodenoson is a pharmacologic stress agent specific to the only adenosine receptor necessary for increased cardiac blood flow, the A<sub>2A</sub> receptor.
Categories: Heterocyclic Compounds, 2-RingSynonyms: 2-((Cyclohexylmethylene)hydrazino)adenosineBrasofensine
go.drugbank.com/drugs/DB04857ExperimentalPhase I/II trials for brasofensine have been completed in the U.K. In November 2001, NeuroSearch confirmed that the drug's development was discontinued in favor of NS 2230.